Business
Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain
Kalytera Announces Formation of Strategic and Scientific Advisory Board to Assist with Development of Cannabinoid-Based Compound for Treatment of Acute and Chronic Pain.
About this update from Claritas Pharmaceuticals Inc.
[{"type":"text","content":"\nSAN FRANCISCO and TEL AVIV, Israel, May 15, 2018 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (OTCQB:KALTF) (the \"Company\" or \"Kalytera\") today announced the formation of a Strategic & Scientific Advisory Board with three key appointments: Professor Joseph Lynch, Ph.D.; Dr. Li Zhang; and Professor Hanns Ulrich Zeilhofer.\n The Strategic and Scientific Advisory Board will work closely with Kalytera’s management to advance the Company’s novel cannabinoid-based technology for the treatment of acute and chronic pain, identify new applications for Kalytera’s cannabinoid technology, and provide insight regarding new cannabinoid-based technologies to complement the Company’s pipeline. \"We are thrilled to have attracted some of the world's leading experts in pain to our Strategic and Scientific Advisory Board,\" said Robert Farrell, Kalytera’s President and Chief Executive Officer. \"The formation of our SSAB further validates the scientific and clinical merit for our pain product and our pipeline of CBD based pharmaceuticals.\" Professor Joseph Lynch, Ph.D.Dr. Lynch completed a BSc majoring in Physics at the University of Melbourne. He then moved to the University of New South Wales to undertake a Masters of Biomedical Engineering, and then a Ph.D. in Physiology. His postdoctoral studies were undertaken in Germany, France and at the Garvan Institute of Medical Research in Sydney. He moved to University of Queensland in 1996 as a Senior Lecturer in the School of Biomedical Sciences, and was awarded an NHMRC Senior Research Fellowship in 2004 (renewed in 2009). He relocated to the Queensland Brain Institute in October 2007. Dr. Li ZhangDr. Zhang has worked as an NIH Staff Scientist in the Laboratory for Integrative Neuroscience since 2004. He is an expert in neuropharmacology, and has published in Nature Chemistry and Biology, including a paper entitled “Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia.” Kalytera’s novel, proprietary cannabinoid-naproxen conjugate is based in part on Dr. Zhang’s pioneering research demonstrating that cannabinoids suppress inflammatory and neuropathic pain by targeting alpha3 glycine receptors. Professor Hanns Ulrich ZeilhoferDr. Zeilhofer studied medicine at the Uni...